CStone Pharmaceuticals (2616) Stock Statistics & Valuation Metrics

CStone Pharmaceuticals has a market cap or net worth of HK$10.74B. The enterprise value is HK$5.33B.

CStone Pharmaceuticals has 1,464,767,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

CStone Pharmaceuticals’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -11.39%.

The current PE Ratio of CStone Pharmaceuticals is ―. CStone Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, CStone Pharmaceuticals had revenue of 407.20M and earned -91.21M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was -187.13M and capital expenditures 0.00, giving a free cash flow of -187.13M billion.

CStone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CStone Pharmaceuticals upcoming earnings date is Mar 26, 2026, TBA (Confirmed).

CStone Pharmaceuticals as a current ratio of 1.60, with Debt / Equity ratio of 97.83%

In the past 12 months, CStone Pharmaceuticals has paid 0.00 in taxes.

CStone Pharmaceuticals EV to EBITDA ratio is -35.65, with an EV/FCF ratio of 0.00.

CStone Pharmaceuticals has HK$672.94M in cash and marketable securities with HK$355.97M in debt, giving a net cash position of -HK$316.96M billion.

Gross margin is 58.98%, with operating margin of -22.52%, and net profit margin of -22.40%.

The average price target for CStone Pharmaceuticals is HK$6.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy